TW
Overview
Tak Wah Mak is a immunology specialist with an H-index of 24 at University Health Network (Member). Has been published in Science, Proceedings of the National Academy of Sciences, Cell Death and Disease. Based in Unknown, Unknown, Global.
Biography
Tak Wah Mak, is a Canadian medical researcher, geneticist, oncologist, and biochemist. He first became widely known for his discovery of the T-cell receptor in 1983 and pioneering work in the genetics of immunology. In 1995, Mak published a landmark paper on the discovery of the function of the immune checkpoint protein CTLA-4, thus opening the path for immunotherapy/checkpoint inhibitors as a means of cancer treatment. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for acute myeloid leukemia in August 2017, becoming the first drug specifically targeting cancer metabolism to be used for cancer treatment. He has worked in a variety of areas including biochemistry, immunology, and cancer genetics.
Affiliations & Institutions
Research Impact
5 Publications
0 Total Citations
Published In
BloodCell Death DifferNat CommunCancer SciHepatology
Key Publications
Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
Immune response in COVID-19: what is next?
Host-derived lipids orchestrate pulmonary γδ T cell response to provide early protection against influenza virus infection.
Nucleolar stress: Molecular mechanisms and related human diseases.
Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
Areas of Expertise
Medical Specialties
Clinical Knowledge & Procedures
Related Specialists
View AllAre you Tak Wah Mak?
Claim your MDRPedia profile to unlock analytics, manage your digital legacy, and receive your verified badge.